Efficacy and safety of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017

Table 4 Efficacy of first-line anti-malarials in three therapeutic efficacy monitoring sites in Angola, 2017

	Efficacy (95% confidence intervals)
	Benguela		Zaire		Lunda Sul
	DP^b	ASAQ^a	AL^a	ASAQ^a	AL^a	DP^b
Uncorrected
Per-protocol day 28	100 (95–100)	99 (94–100)	92.8 (85–97)	82.2 (72–89)	90.1 (82–95)	100 (95–100)
Per-protocol day 42	94.6 (87–98)	–	–	–	–	100 (95–100)
Kaplan–Meier estimate day 28	100 (100–100)	98.9 (97–100)	92.7 (88–98)	82.1 (75–90)	90.1 (84–96)	100 (100–100)
Kaplan–Meier estimate day 42	94.6 (90–99)	–	–	–	–	100 (100–100)
PCR-corrected
Per-protocol day 28	100 (97–100)	100 (97–100)	95.5 (89–98)	93 (85–97)	96.4 (90–99)	100 (96–100)
Per-protocol day 42	100 (96–100)	–	–	–	–	100 (96–100)
Kaplan–Meier estimate day 28	100	100 (97–100)	95.5 (91–100)	93.3 (88–99)	96.5 (93–100)	100
Kaplan–Meier estimate day 42	100 (96–100)	–	–	–	–	100

Per-protocol efficacy defined as proportion adequate clinical and parasitological response, Kaplan–Meier estimate calculated from estimate of survival function
AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, DP dihydroartemisinin–piperaquine
^a28-day follow up
^b42-day follow up

ISSN: 1475-2875